Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.32 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12247866 | 0.82 | — | — | |
| SCHEMBL2554745 | 0.82 | GABRR1 (0.52) | ALDH1A1GABRR1GABRR2GRM2GRM3 | |
| SCHEMBL26951594 | 0.80 | GABRR1 (0.31) | GABRR1GABRR2 | |
| SCHEMBL14231527 | 0.78 | MEN1 (0.30) | ALDH1A1GABRR1GABRR2MEN1KMT2A | |
| SCHEMBL15374642 | 0.78 | CA1 (0.32) | ALDH1A1TDP1GABRR1GABRR2 | |
| SCHEMBL18459537 | 0.77 | DPP4 (0.33) | — | |
| SCHEMBL26520126 | 0.75 | GBA1 (0.31) | — | |
| SCHEMBL16850622 | 0.75 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL23844625 | 0.74 | CA1 (0.46) | ALDH1A1 | |
| SCHEMBL2186293 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010130672-A1 | AZABICYCLO [4.1.0] HEPTANE DERIVATIVES AND THEIR USE AS MONOAMINE REUPTAKE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |